Vladimir Gubala

Vladimir Gubala

Auto-generated profile, based on publicly available information

Vladimir Gubala

Dublin City University

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2011 in Analytical Chemistry
Verified
Journal Article
Closed access
VGVladimir Gubala
Vladimir Gubala
LHLeanne F. Harris
Leanne F. Harris
ARAntonio Ricco
Antonio Ricco
MTMing X. Tan
Ming X. Tan
DWDavid E. Williams
David E. Williams

1 May 2008 in Hypertension
Verified
Journal Article
Closed access
JPJosé A. Hernández Prada
José A. Hernández Prada
AFAnderson J. Ferreira
Anderson J. Ferreira
MKMichael J. Katovich
Michael J. Katovich
VSVinayak Shenoy
Vinayak Shenoy
YQYanfei Qi
Yanfei Qi
MRMohan K. Raizada
Mohan K. Raizada
Angiotensin-converting enzyme 2 (ACE2) is a key renin-angiotensin system enzyme involved in balancing the adverse effects of angiotensin II on the cardiovascular system, and its overexpression by gene transfer is beneficial in cardiovascular disease. Therefore, our objectives were 2-fold: to identify compounds that enhance ACE2 activity using a novel conformation-based rational drug discovery strategy and to evaluate whether such compounds reverse hypertension-induced pathophysiologies. We used a unique virtual screening approach. In vitro assays revealed 2 compounds (a xanthenone and resorcinolnaphthalein) that enhanced ACE2 activity in a dose-dependent manner. Acute in vivo administration of the xanthenone resulted in a dose-dependent transient and robust decrease in blood pressure (at 10 mg/kg, spontaneously hypertensive rats decreased 71±9 mm Hg and Wistar-Kyoto rats decreased 21±8 mm Hg; P <0.05). Chronic infusion of the xanthenone (120 μg/day) resulted in a modest decrease in the spontaneously hypertensive rat blood pressure (17 mm Hg; 2-way ANOVA; P <0.05), whereas it had no effect in Wistar-Kyoto rats. Strikingly, the decrease in blood pressure was also associated with improvements in cardiac function and reversal of myocardial, perivascular, and renal fibrosis in the spontaneously hypertensive rats. We conclude that structure-based screening can help identify compounds that activate ACE2, decrease blood pressure, and reverse tissue remodeling. Administration of ACE2 activators may be a valid strategy for antihypertensive therapy.

25 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ATAmanda Tivnan
Amanda Tivnan
WOWayne Shannon Orr
Wayne Shannon Orr
VGVladimir Gubala
Vladimir Gubala
RNRobert Nooney
Robert Nooney
DWDavid E Williams
David E Williams
RSRaymond Stallings
Raymond Stallings
Neuroblastoma is one of the most challenging malignancies of childhood, being associated with the highest death rate in paediatric oncology, underlining the need for novel therapeutic approaches. Typically, patients with high risk disease undergo an initial remission in response to treatment, followed by disease recurrence that has become refractory to further treatment. Here, we demonstrate the first silica nanoparticle-based targeted delivery of a tumor suppressive, pro-apoptotic microRNA, miR-34a, to neuroblastoma tumors in a murine orthotopic xenograft model. These tumors express high levels of the cell surface antigen disialoganglioside GD2 (GD2), providing a target for tumor-specific delivery. Nanoparticles encapsulating miR-34a and conjugated to a GD2 antibody facilitated tumor-specific delivery following systemic administration into tumor bearing mice, resulted in significantly decreased tumor growth, increased apoptosis and a reduction in vascularisation. We further demonstrate a novel, multi-step molecular mechanism by which miR-34a leads to increased levels of the tissue inhibitor metallopeptidase 2 precursor (TIMP2) protein, accounting for the highly reduced vascularisation noted in miR-34a-treated tumors. These novel findings highlight the potential of anti-GD2-nanoparticle-mediated targeted delivery of miR-34a for both the treatment of GD2-expressing tumors, and as a basic discovery tool for elucidating biological effects of novel miRNAs on tumor growth.

10 November 2004 in Organic Letters
Verified
Journal Article
Closed access
VGVladimir Gubala
Vladimir Gubala
JBJosé E. Betancourt
José E. Betancourt
JRJosé M. Rivera
José M. Rivera

13 April 2010 in Journal of Materials Chemistry
Verified
Journal Article
Closed access
PDF file
RGRam P. Gandhiraman
Ram P. Gandhiraman
CVCedric Volcke
Cedric Volcke
VGVladimir Gubala
Vladimir Gubala
CDColin Doyle
Colin Doyle
LBLourdes Basabe-Desmonts
Lourdes Basabe-Desmonts
DWDavid E. Williams
David E. Williams
Point-of-care (POC) diagnostics implementing microfluidic technology on single use disposable plastic chips has potential applications in personalized medicine, clinical diagnostics and global health. However, the challenges in commercializing POC devices must be addressed. Immobilization of biomolecules to plastic chips through appropriate surface functionalization is a key issue for the fabrication of new generation biomedical diagnostic devices. The most important requirements for a practicable surface functionalization process are speed, control and reliability. Plasma-based methods can meet these criteria. A single step, solventless, ecofriendly and high throughput nature of plasma processing makes them highly attractive. Here we demonstrate the efficient surface functionalization of a next-generation biosensor material, a chemically inert cycloolefin polymer (COP). The plasma formation of a surface-bound aminated siloxane network from mixed aminopropyltriethoxysilane and ethylenediamine precursors allowed us to form a well-adherent film with an exceptionally high degree of amine functionalization. We deduce that the siloxane was the critical component for radical insertion into the COP and for building a stable network to support the reactive amine functionalities. We present a full physical and chemical characterization of the films, including a detailed study of their swelling in water, using an array of surface analytical techniques: X-ray photoelectron spectroscopy, X-ray reflectivity, reflection infra-red spectroscopy, atomic force microscopy (AFM) and fluorophore binding reactions. We demonstrate an original approach for qualitatively analyzing the distribution of amine functionalities by counting surface-bound functionalized silica nanoparticles in the AFM. The relative contributions from covalent (specific) and non-covalent (non-specific) reaction chemistry assessed using 3′-fluorescein-labeled ssDNA attachment showed that the non-specific binding could be reduced significantly according to the particular feed gas mixture used to prepare the coating. A reaction mechanism has been proposed for the deposition of amine functionalities on COP plastic and also for enhancing the amine functionalities that affect the non-specific binding significantly.

27 June 2018 in Pure and Applied Chemistry
Verified
Journal Article
Open access
PDF file
VGVladimir Gubala
Vladimir Gubala
Linda J. JohnstonLinda J. Johnston
Linda J. Johnston
ZLZiwei Liu
Ziwei Liu
HKHarald Krug
Harald Krug
CMColin J. Moore
Colin J. Moore
MVMichel Vert
Michel Vert
Nanotechnology is a rapidly evolving field, as evidenced by the large number of publications on the synthesis, characterization, and biological/environmental effects of new nano-sized materials. The unique, size-dependent properties of nanomaterials have been exploited in a diverse range of applications and in many examples of nano-enabled consumer products. In this account we focus on Engineered Nanomaterials (ENM), a class of deliberately designed and constructed nano-sized materials. Due to the large volume of publications, we separated the preparation and characterisation of ENM from applications and toxicity into two interconnected documents. Part 1 summarizes nanomaterial terminology and provides an overview of the best practices for their preparation, surface functionalization, and analytical characterization. Part 2 (this issue, Pure Appl. Chem. 2018; 90(8): 1325–1356) focuses on ENM that are used in products that are expected to come in close contact with consumers. It reviews nanomaterials used in therapeutics, diagnostics, and consumer goods and summarizes current nanotoxicology challenges and the current state of nanomaterial regulation, providing insight on the growing public debate on whether the environmental and social costs of nanotechnology outweigh its potential benefits.